Nasdaq
$1.38▼ 2.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.1MShares out 3.7M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
1- 8.13Regular26.08.14 01:40SCHEDULE 13G/AOwnership#●●●#●●●
Enveric Biosciences, Inc.
Ayrton Capital LLC has filed a Schedule 13G/A regarding its beneficial ownership in Enveric Biosciences, Inc. This filing reports a change in the equity holdings of the investor, indicating an adjustment in the company's ownership structure.…more
$1.38-2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
News
GlobeNewswire- 3d agoPre-market26.10.21 21:01#●●●#●●●
Enveric Biosciences Reports Favorable Preclinical Results for EB-003
Enveric Biosciences announced positive preclinical data for its lead psychiatric drug candidate, EB-003, supporting its advancement toward human clinical trials. While this marks a key development milestone, the company remains in the early stages of drug discovery without commercial revenue.…more
$1.38-2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.15Pre-market26.09.15 21:06
●●●●●●●● ●●●●● ●●●●●●
Enveric Biosciences has received a notice of allowance for its third U.S. patent covering the EVM401 series of non-hallucinogenic neuroplastogens. This patent strengthens the company's intellectual property portfolio for proprietary compounds targeting psychiatric and neurological disorders like PTSD.…more
$1.38-2.47%vs prev closeShareBenzinga
1 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report